Efficacy and Safety of Once-Weekly Semaglutide vs. Exenatide ER after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 3)

      Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue in phase 3 development for the treatment of type 2 diabetes (T2D). In this 56-week, open-label study, 813 adults with T2D inadequately controlled on 1 to 2 oral antidiabetic drugs (OADs; metformin, sulfonylurea, thiazolidinediones) were randomized 1:1 to once-weekly semaglutide 1.0 mg or once-weekly exenatide extended release (ER) 2.0 mg. Primary endpoint was change in glycated hemoglobin (HbA1c) from baseline to Week 56.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Diabetes
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect